OOIR: Observatory of International Research

Papers

(The H4-Index of Brain is 72. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19	276
COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital	266
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease	249
Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome	222
Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state	221
How patients with multiple sclerosis acquire disability	200
Sleep deprivation impairs molecular clearance from the human brain	182
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease	165
CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease	163
Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons	151
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum	143
Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI	143
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options	142
Neurovascular injury with complement activation and inflammation in COVID-19	141
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease	140
Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis	131
Emerging roles for dynamic aquaporin-4 subcellular relocalization in CNS water homeostasis	127
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease	125
The potential of serum neurofilament as biomarker for multiple sclerosis	124
To what degree is late life cognitive decline driven by age-related neuropathologies?	120
An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas	117
Detection of neuron-derived pathological α-synuclein in blood	117
Acute and non-resolving inflammation associate with oxidative injury after human spinal cord injury	115
Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease	113
Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management	106

Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis	106
The synapse in traumatic brain injury	106
Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics	106
Hearing and dementia: from ears to brain	105
Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder	105
Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability	105
18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases	104
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory	103
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease	99
The Developing Human Connectome Project: typical and disrupted perinatal functional connectivity	97
Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial	97
Depression, dementia and immune dysregulation	96
Multimodal neuroimaging in post-COVID syndrome and correlation with cognition	96
Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants	95
The GGC repeat expansion inNOTCH2NLCis associated with oculopharyngodistal myopathy type 3	93
Developmental and epileptic encephalopathies: what we do and do not know	91
The role of noradrenaline in cognition and cognitive disorders	90
Consciousness among delta waves: a paradox?	90
The development and convergence of co-pathologies in Alzheimer’s disease	89
The microglial component of amyotrophic lateral sclerosis	89
Studying human nociceptors: from fundamentals to clinic	89
Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis	89
Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy	88
Models of psychedelic drug action: modulation of cortical-subcortical circuits	88
Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies	87
Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration	87
COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis	86
The extracellular matrix as modifier of neuroinflammation and remyelination in multiple sclerosis	86
Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications	83
Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence	82
The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease	82
Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial	80
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects	80
Macrophage phagocytosis after spinal cord injury: when friends become foes	79
Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease	78
Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats	78
Towards network-guided neuromodulation for epilepsy	77
Local sleep-like cortical reactivity in the awake brain after focal injury	77
Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer’s disease	77
Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder	76
COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations	76
A new science of emotion: implications for functional neurological disorder	75
RFC1 expansions are a common cause of idiopathic sensory neuropathy	74
Microglial activation and blood–brain barrier permeability in cerebral small vessel disease	74
Anti-amyloid antibody therapies in Alzheimer’s disease	73
A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene	73
Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging	72
Damage to Broca’s area does not contribute to long-term speech production outcome after stroke	72
Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms	72